LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ

Published:2016-06-02 Issue:1 Volume:8 Page:
ISSN:1758-5996
Container-title:Diabetology & Metabolic Syndrome
language:en
Short-container-title:Diabetol Metab Syndr

Author:

Rutten Guy E. H. M., ,Tack Cees J.,Pieber Thomas R.,Comlekci Abdurrahman,Ørsted David Dynnes,Baeres Florian M. M.,Marso Steven P.,Buse John B.

Funder

Novo Nordisk (DK) sponsored the LEADER trial

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13098-016-0153-5

Reference19 articles.

1. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823–30.

2. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008–17.

3. Saunders C, Byrne CD, Guthrie B, Lindsay RS, McKnight JA, Philip S, Sattar N, Walker JJ, Wild SH, Scottish Diabetes Research Network Epidemiology Group. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30:300–8.

4. Rivers D, August EM, Sehovic I, Lee Green B, Quin GP. A systematic review of the factors influencing African American’s participation in cancer clinical trials. Contem Clin Trials. 2013;35:13–32.

5. Weiss CO, Boyd CM, Wolff JL, Leff B. Prevalence of diabetes treatment effect modifiers: the external validity of trials of older adults. Aging Clin Exp Res. 2012;24:370–6.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats;Biochemical and Biophysical Research Communications;2022-11

2. Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota;Frontiers in Molecular Biosciences;2022-06-15

3. Beneficial effects of liraglutide on peripheral blood vessels;Vojnosanitetski pregled;2020

4. Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: A target to modulate cardiovascular risk?;International Journal of Cardiology;2019-10

5. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction;Cardiology Clinics;2019-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3